Is the EU Joint Clinical Assessment just another administrative layer, or the start of a truly European HTA?
In this MAP episode, Dr. Stefan Walzer talks with Dr. Oriol Solà-Morales, physician, health economist, founder and CEO of HITT and founding member of EUnetHTA, about what the first JCA reports reveal.
Drawing on Spain’s shift from regional to coordinated HTA, Oriol sees the JCA’s potential to build Europe. He describes a deliberately conservative start: concise PICO consolidation, uncertainties named but not resolved, and a clear line between the European assessment and national reimbursement decisions. They discuss how countries like Germany may gradually adapt, for example on indirect comparisons and progression-free survival, and why JCA requirements belong in development planning by the end of phase I. Success, in his view, means more transparency and a stable, predictable environment for development in Europe.
Connect with Oriol on LinkedIn: https://www.linkedin.com/in/oriol-sol%C3%A0-morales-a130692/